연구성과로 돌아가기
2023 연구성과별 연구자 정보 (395 / 2675)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Alcindor, Thierry | Alcindor, T | 17 | McGill Univ, Hlth Ctr, Montreal, PQ, Canada | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Sym, Sun Jin | Sym, SJ | 18 | Gachon Univ, Gil Med Ctr, Incheon, South Korea | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Song, Eun-Kee | Song, EK | 19 | Jeonbuk Natl Univ, Med Sch, Jeonju, South Korea | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Chee, Cheng Ean | Chee, CE | 20 | Natl Univ Canc Inst, Singapore, Singapore | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Chao, Yee | Chao, Y | 21 | Taipei Vet Gen Hosp, Taipei, Taiwan | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Kim, Sunnie | Kim, S | 22 | Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA | J-2750-2012 | Kim, Tae-You | ykkang@amc.seoul.kr; | |||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Kim, Sunnie | Kim, S | 22 | Univ Colorado, Canc Ctr, Aurora, CO USA | J-2750-2012 | Kim, Tae-You | ykkang@amc.seoul.kr; | |||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Oh, Do-Youn | Oh, DY | 23 | Seoul Natl Univ, Seoul Natl Univ Hosp, Grad Sch, Canc Res Inst,Coll Med,Integrated Major Innovat M, Seoul, South Korea | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Yen, Jennifer | Yen, J | 24 | Guardant Hlth, Redwood City, CA USA | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Odegaard, Justin I. | Odegaard, JI | 25 | Guardant Hlth, Redwood City, CA USA | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Lagow, Errin | Lagow, E | 26 | Guardant Hlth, Redwood City, CA USA | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Li, Daner | Li, D | 27 | MacroGenics, Rockville, MD USA | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Sun, Jichao | Sun, JC | 28 | MacroGenics, Rockville, MD USA | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Kaminker, Patrick | Kaminker, P | 29 | MacroGenics, Rockville, MD USA | ykkang@amc.seoul.kr; | |||||
| Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma | Moore, Paul A. | Moore, PA | 30 | MacroGenics, Rockville, MD USA | ykkang@amc.seoul.kr; |
페이지 이동: